News for PAVmed Inc. (PAVM)

PR NewswireNEW YORK, July 16, 2025 Virtual public CAC meeting to be held September 4, 2025, at 2:00 p.m. ETNEW YORK, July 16, 2025 /PRNewswire/ -- Lucid Di

PR NewswireNEW YORK, June 18, 2025 Lucid to partner with Hoag in its mission to eradicate esophageal cancer by expanding access to EsoGuard precancer testi

In recent developments, Ascendiant Capital has maintained its "Buy" rating on PAVmed (PAVM) with the latest update issued by the analyst Edward Woo. Despite the

PAVmed's (PAVM) digital health subsidiary, Veris Health, has formed a strategic alliance with The Ohio State University Comprehensive Cancer Center ”“ Arthur G

PAVmed's subsidiary Veris Health partners with OSUCCC - James following successful pilot. Strategic agreement includes EHR integration and clini

PR NewswireNEW YORK, May 27, 2025 NEW YORK, May 27, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-sta

Lucid Diagnostics (LUCD) to be included in the Russell 2000® and Russell 3000® indexes effective June 27, 2025. Inclusion increases visibility to inst

Release Date: May 15, 2025For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points PAVmed Inc (PAVM)

Refinitiv StreetEvents Event TranscriptE D I T E D V E R S I O NPAVM.OQ - PAVmed IncQ1 2025 PAVmed Inc Earnings CallMay 15, 2025 / 12:30PM GMT ===============

PR NewswireNEW YORK, May 15, 2025 Lucid secured capital to extend runway well past key upcoming reimbursement milestones; ended 1Q25 with over $40 million

Revenue: Lucid Diagnostics recognized $0.8 million in EsoGuard® Esophageal DNA Test revenue for Q1 2025, significantly surpassing the estimated revenue of $0.

Lucid Diagnostics processed 3,034 EsoGuard tests in Q1, generating $0.8M in revenue. PAVmed (PAVM) reported a GAAP net income of $17.7M, but a non-GAAP

Key Highlights: PAVmed (PAVM) surpasses EPS expectations with a Non-GAAP EPS of -$0.16. Revenue decreases by 17.8% year-over-year but still exceeds forec

Discover PAVmed's Q1 earnings report with EPS improving by 70.7% Y/Y. Learn about the projections, past performance, and what it means for investors.

PR NewswireNEW YORK, May 14, 2025 Processed 3,034 EsoGuard® tests and recognized revenue of $0.8 million in 1Q25Secured capital to extend runway well past

PR NewswireNEW YORK, April 11, 2025 NEW YORK, April 11, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial

Lucid Diagnostics (LUCD) successfully raised $16.1 million in net proceeds from a public offering. The offering included 14,375,000 shares at $1.20 per

PR NewswireNEW YORK, April 9, 2025 NEW YORK, April 9, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-s

PR NewswireNEW YORK, April 9, 2025 NEW YORK, April 9, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-s